Craniospinal giant cell tumors: clinicoradiological analysis in a series of 11 cases

Sharma, Rewati Raman; Mahapatra, Ashok Kumar; Pawar, Sanjay J.; Sousa, J; Dev, Ebenezer J.

doi:10.1054/jocn.2001.0963

Cited by 37 publications

(32 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 All reports in the literature that present angiographic data for cases of GCT indicate that the tumors are richly vascularized via the internal or external carotid artery. 3,11,13,22,26,27,31,41,45,47,48 Aneurysmal bone cysts are considered to be the result of a trauma-or tumor-induced anomalous vascular process. 33 However, the secondary features of the aneurysmal bone cyst change in our case may support a relationship with the prior hemorrhage and reparative reaction in the hypervascularized tumor.…”

Section: Discussionmentioning

confidence: 99%

Giant cell tumor of the temporal bone with intratumoral hemorrhage

Matsushige

Nakaoka

Yahara

et al. 2008

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Giant cell tumor of the temporal bone with intratumoral hemorrhage

Matsushige

Nakaoka

Yahara

et al. 2008

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…Involvement of zygomatic bone is extremely uncommon and we believe this to be only the third case of such an entity in our search of pertinent medical literature (Table I). The patients with head and neck giant cell tumour may present with swelling, pain, epistaxis, neurological deficits, proptosis, visual defects, tinnitus and hearing loss depending upon the location of lesion [5,10]. Our patient was asymptomatic except for an infraorbital swelling which made her come to us.…”

Section: Discussionmentioning

confidence: 69%

“…Giant cell tumours exhibit a peak age incidence between 20 and 30 years with a female preponderance [10]. Our patient was a 36-year-old female.…”

Section: Discussionmentioning

confidence: 78%

“…Curettage results in a recurrence rate of up to 70%, whereas recurrence after wide resection is about 7% [14]. Many recent reports advocate the use of radiotherapy in the management of giant cell tumour [8,10]. Other treatment modalities that have been used include: chemotherapy [15], cryosurgery [13] and curettage with use of adjuvant agents [16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Giant cell tumour (osteoclastoma) of the zygoma: An extremely unusual neoplasm

Sethi

Passey

Mrig

et al. 2006

Acta Oto-Laryngologica

View full text Add to dashboard Cite

show abstract

“…RT can reduce the recurrence rate after surgery, and, furthermore, it can be used for SGCT patients not suitable for surgery20, 21, 22. Advances in RT technology may improve its effectiveness; however, high‐level evidence for the effectiveness of these therapies is lacking, and some authors have even found that RT does not improve recurrence rates6, 23.…”

Section: Discussionmentioning

confidence: 99%

Recurrence of Giant Cell Tumor of the Spine after Resection: A Report of 10 Cases

Lin

Teng

et al. 2018

Orthopaedic Surgery

View full text Add to dashboard Cite

ObjectiveTo review the clinical details and further treatments for recurrent spinal giant cell tumors (SGCT), and to analyze the risk factors of recurrence and shed new light on the treatment options and prognosis of recurrent SGCT.MethodsA retrospective analysis of recurrent SGCT between April 2003 and January 2014 was performed. A total of 10 patients comprising 3 men and 7 women with a mean age of 28.9 years (range, 21–40 years) were included in the study. All complete clinical data, radiographs, CT, MRI, scans and pathological data were reviewed. The tumor locations and the regions involved were evaluated by CT and MRI. The blood supply of the tumors was evaluated by enhanced CT and MRI. The mean follow‐up was 81.3 months (range, 35.7–172.1 months).ResultsAll patients had Enneking stage 3 tumors; 9 (90%) of them had different extents of spinal canal involvement in the primary time period. All patients underwent intralesional resection during their first surgery. Only 1 patient received local adjuvant treatments; no patient underwent selective arterial embolization or used denosumab at that time. Only 1 patient underwent adjuvant radiotherapy postoperatively, and another patient used bisphosphonates. After recurrence, 1 patient was cured using denosumab, and 2 patients' disease was controlled through use of other medical treatments or adjuvant treatments. There were 3 repeated recurrences and 7 repeated surgical procedures were performed in 5 patients. There were 6 intralesional excisions and 1 decompression surgery. The mean relapse‐free time after the first surgery was 32.3 months (range, 10.5–62.6 months). The overall mean relapse‐free time was 40.2 months (range, 10.5–157 months). No distant metastasis was found in our series. At the final follow‐up, 4 patients were disease free, 3 patients' disease was under control, 2 has progressive disease aggravation, while 1 patient died as a result of progression of disease 133.9 months after first surgery.ConclusionIntralesional excision for recurrent spinal giant cell tumors is an effective option that may have satisfactory prognosis. However, the excision and the inactivation of the lesion should be carried out carefully and thoroughly without missing any corners. Early diagnosis of recurrence may be associated with better prognosis. Adjuvant treatments perioperatively and systemic medical treatments can decrease recurrence rates and can have therapeutic effects in the recurrent SGCT.

show abstract

Craniospinal giant cell tumors: clinicoradiological analysis in a series of 11 cases

Cited by 37 publications

References 30 publications

Giant cell tumor of the temporal bone with intratumoral hemorrhage

Giant cell tumor of the temporal bone with intratumoral hemorrhage

Giant cell tumour (osteoclastoma) of the zygoma: An extremely unusual neoplasm

Recurrence of Giant Cell Tumor of the Spine after Resection: A Report of 10 Cases

Contact Info

Product

Resources

About